The use of other potential approaches includes therapeutic vaccines against HCC tumor-associated antigens (such as glypican-3, alpha-feto protein), as well as the use of oncolytic viruses such as the orthoreovirus to modulate innate immune response[96–98]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.